LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Adaptive Biotechnologies Corp

Geschlossen

10.28 -1.06

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.22

Max

10.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.9M

-30M

Verkäufe

5M

52M

EPS

-0.2

Gewinnspanne

-56.881

Angestellte

619

EBITDA

-3.3M

-30M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+5.67% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

433M

1.6B

Vorheriger Eröffnungskurs

11.34

Vorheriger Schlusskurs

10.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Juni 2025, 22:33 UTC

Akquisitionen, Fusionen, Übernahmen

Millicom to Acquire Telefonica Ecuador for $380 Million

14. Juni 2025, 01:24 UTC

Akquisitionen, Fusionen, Übernahmen

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13. Juni 2025, 23:50 UTC

Akquisitionen, Fusionen, Übernahmen

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13. Juni 2025, 23:20 UTC

Akquisitionen, Fusionen, Übernahmen

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13. Juni 2025, 23:09 UTC

Akquisitionen, Fusionen, Übernahmen

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13. Juni 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13. Juni 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Millicom to Acquire Telefonica Ecuador for $380M

13. Juni 2025, 22:04 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Better Data Facilitate Investments In Oil Patch -- Market Talk

13. Juni 2025, 21:42 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13. Juni 2025, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Bunge: Outside Date Extended to July 3

13. Juni 2025, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13. Juni 2025, 21:34 UTC

Akquisitionen, Fusionen, Übernahmen

Bunge Gets Mexico Approval for Viterra Deal

13. Juni 2025, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Bunge Gets China Approval for Viterra Deal

13. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Juni 2025, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13. Juni 2025, 20:34 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- Update

13. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13. Juni 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13. Juni 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13. Juni 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13. Juni 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13. Juni 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13. Juni 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13. Juni 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13. Juni 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13. Juni 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13. Juni 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13. Juni 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Peer-Vergleich

Kursveränderung

Adaptive Biotechnologies Corp Prognose

Kursziel

By TipRanks

5.67% Vorteil

12-Monats-Prognose

Durchschnitt 11 USD  5.67%

Hoch 13 USD

Tief 9 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Adaptive Biotechnologies Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

7

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.81 / 10.18Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.